cs32582
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 28, 2024 (NCT06224595)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07129382 | Phase 1/Phase 2 (Phase 2) | Sep 8, 2025 | Chipscreen Biosciences, Ltd. |
| NCT06224595 | Phase 1 | Mar 28, 2024 | Chipscreen Biosciences, Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chipscreen Biosciences, Ltd. | For profit | 2 | 2 | 2 | 2024 |
1 organizations
Page 1 / 1